Cricut, Inc. reported an 11% revenue increase to $188.6 million in Q3 2026, driven by 17% growth in product sales and 4% growth in platform revenue. Net income rose 36% to $27.8 million, supported by a growing subscriber base of 3.07 million and expanding international sales. The company announced a recurring semi-annual dividend of $0.10 per share and a special dividend of $0.70 per share to be paid in January 2027, reflecting strong cash flow and a balanced capital allocation strategy. Cricut continues to invest in innovation and international expansion, aiming to deepen user engagement and sustain long-term growth.
Cricut, Inc. reported strong Q3 2026 financial results including an 11% revenue increase to $188.6 million. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Nov 04, 2026 03:41 WIB: out of 134 priced US stocks, 42 rose and 91 fell. Notable movers include JMKE at USD 19.69 with a 4.68% gain and 100% sell order activity, and STLA at USD 4.51 down 4.45%.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
